Answers are grounded in this paper and cite their sources.
Immune checkpoint inhibitor therapy has been introduced into cancer clinics for over a decade with big hopes and hypes, yet the true mechanism behind this therapy is still unclear in many ways. In a previous article we have introduced a new working model for this therapy based on the partial depletion of PD1 positive T cells. This model, as we called it the depletion model, explains all clinical observations including the trigger effect and the hyper-progression associated with anti-PD1/PDL1 antibody use. One critical prediction from this model is that under repeated dosing of anti-PD1 antibody, any antitumor response must be mediated by PD1-negative T cells, because that all PD1-positive T cells are removed by the antibody. Unless this prediction can be confirmed, the depletion model will not be supported by evidence. In this report, using few real-world cases, we provide supporting evidence to support the various aspects of the depletion model.
No takes yet. Share an insight, caveat, or question.
Tsung et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: